BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

This article was originally published here

The phase 3 CheckMate -498 trial assessing Opdivo plus radiation against temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not achieve

The post BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply